What's New
Last Posted: Oct 15, 2019
- Exome Sequencing Reveals a High Prevalence of BRCA1 and BRCA2 Founder Variants in a Diverse Population-Based Biobank
NS Abul-Husn et al, BioRXIV, October 13, 2019 - Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
Peters Brandilyn A et al. Genome medicine 2019 Oct (1) 61 - Resistance to Immune Checkpoint Blocker May Be Linked to Metabolic Imbalance
ASCO Post, October 10, 2019 - Pancreatic Cancer: Patient Page
JAMA, October 2019 - New Precision Medicine Treatment Could Benefit Many Men with Treatment-Resistant Metastatic Prostate Cancer
by Andrea K. Miyahira, Prostate Cancer Foundation, October 1, 2019 - Easing the Burden of Children and Families Dealing with Cancer
JE Bloyd, CDC Cancer Blog, October 2019 - General “Take Action” Infographic
CDC Cancer, 2019 - Genome-wide germline correlates of the epigenetic landscape of prostate cancer
KE Houlahan et al, Nature Medicine, October 7, 2019 - Liquid biopsy: one cell at a time
SB Lim et al, NPJ Precision Oncology, October 2019 - A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer
H Nasief et al, NPJ Precision Oncology, October 4, 2019 - Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility—Pandora’s Box Is Opening Wider
JAMA Oncology, October 2019 - A Patient’s Guide to Endometrial Cancer-This cancer is on the rise. But early detection saves lives.
MO Shroeder, US News, October 4, 2019 - Implementation Science Centers in Cancer Control (ISC3)
NCI, October 2019 - A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
L Sun et al, JAMA Oncology, October 3, 2019 - After a Breast Cancer Diagnosis, Men May Be More Likely to Die than Women
NCI, October 2, 2019
.png)
No hay comentarios:
Publicar un comentario